Skip to main content

lopinavir/ritonavir (Kaletra®)

 

Status: Medicine does not meet criteria for AWMSG assessment

Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information.

Medicine details

Medicine name lopinavir/ritonavir (Kaletra®)
Formulation 100 mg/25 mg film-coated tablet
Reference number 190
Indication

Treatment of HIV-1 infected adults and children above the age of 2 years, in combination with other antiretroviral agents

Company AbbVie Ltd
BNF chapter Infections
Assessment type N/A
Status Medicine does not meet criteria for AWMSG assessment
Date of issue 21/02/2008
Follow AWTTC: